Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns

1As the worldwide population ages, over 50 million people are now living with dementia, and this number is set to increase to 152 million by 2050. Dementia has reached epidemic proportions, with major social, medical, and economic burdens. The leading cause of dementia is Alzheimer’s disease (AD), whose main clinical manifestation is cognitive impairment, but 80% of AD patients also show various behavioural and psychological symptoms, collectively known as neuropsychiatric symptoms (NPSs). These symptoms are associated with more rapid progression to severe dementia and an earlier death. They also adversely reduce the quality of life of patients and caregivers.

2Cross-sectional and longitudinal studies have indicated that different NPSs occur mostly at different stages of AD. For example, hallucinations seem to be more common in patients with severe AD, while irritability tends to occur in the early stages of the disease. Even if some NPSs seem to appear together and share some of the same pathological features (for example, both depression and apathy are expressed as loss of interest and motivation), they have different pathological mechanisms. A clear understanding of the pathological mechanisms of differential NPSs is crucial for the early detection and treatment of the disease and the NPSs.

3Many empirical studies have been conducted to understand the neural pathogenesis of NPSs in AD and its role in the progression of AD primarily using neuroimaging techniques. Yet, there has only been a small, though growing, number of reviews on this body of literature. Moreover, most of these reviews were merely of qualitative with regard to the brain regions associated with NPSs. In our current efforts, we attempted to provide a more comprehensive review focusing on the quantitative aspects of relevant reports available in the literature. In doing so, we will manage to summarize the number of significant associations between NPSs and brain regions to describe quantitatively symptom-general and -specific patterns of brain lesions, so that we can determine the core damage regions of each symptom, with more detailed pathological information of NPSs in AD.

4Accurate assessments of NPSs are the basis of NPSs pathogenesis neuroimaging research. Although these assessments are well-established and available in the NPSs literature with or without the use of neuroimaging, reviews of NPSs have only briefly summarized these NPSs test. We believe that a more detailed description of these tests is needed, including the applicable population of the tests, their advantages and disadvantages, among others. More importantly to the study of AD, we cannot ignore the problem of assessing NPSs in AD patients, accurate assessment of whose neurological and behavioural symptoms is critical and yet compounded with NPSs. Finally, a number of researches have shown that the onset time and the association of NPSs with different cognitive domains are variable, better understanding of which helps to comprehend the association between NPSs and AD. To the best of our knowledge, such issues have not been systematically summarized in review.

5Overall, the current understanding of the pathological mechanism of NPSs in patients with AD is limited, especially the relationship between NPSs and AD, so a systematic review is needed to clarify these problems. We therefore provide an extensive review to 1) summarize the clinical assessment, onset time, and association with cognitive impairment of NPSs, and 2) quantitatively describe symptom-general and -specific patterns of brain lesions and brain circuits; and 3) elucidate the associations between the NPSs and AD.

6We performed a systematic literature review following the guidelines for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, http://www.prisma-statement.org/). Research papers published up to March 2020 were identified in the databases PubMed and PsycINFO databases, using the following terms: ‘Alzheimer disease’ or ‘mild cognitive impairment’ AND ‘neuropsychiatric symptoms’, ‘apathy’, ‘delusions’, ‘depression’, ‘agitation’, ‘hallucination’, ‘anxiety’, ‘euphoria’, ‘disinhibition’, ‘irritability’, ‘aberrant motor behavior’, ‘sleep disturbances’, ‘appetite disturbances’, or ‘eating disorder’. The selection criteria were as follows: (1) To limit the heterogeneity, we focused only on AD and excluded studies that included non-AD dementia and non-amnesic MCI; (2) To ensure the reliability of the research results, articles with a sample size less than 10 were excluded; (3) Articles with subjects younger than 50 years of age were excluded.

7All included original manuscripts were assessed by two independent reviewers to avoid possible bias and reporting quality using the Joanna Briggs Institute-Qualitative Assessment and Review instrument (JBI-QARI). Six papers were considered low quality and were excluded. Twenty-five papers comparing the pathological mechanisms of subjects with and without NPSs, without matching confounding variables such as age and cognitive ability, but without methodological problems, were rated as of moderate quality. The rest of the papers were rated as high quality with low bias.

8Finally, 114 studies were included, including 66 neuroimaging studies to explore the pathological mechanism of NPSs and 48 non-imaging studies to summarize clinical assessments of NPSs (N = 25), onset times of NPSs (N = 8), and the associations of NPSs with cognitive impairment (N = 15). sFigure 1 summarizes the process for study selection and inclusion. AD is defined by the standard diagnostic criteria, primarily NINCDS-ADRDA (approximately 78%), followed by the CDR, DSM-IV, and CERAD. Amnestic MCI (aMCI) is defined by Petersen criteria.

9In this section, we will first summarize the existing clinical assessment scales of NPSs and discuss the main problems these assessments have when used to measure NPSs in AD patients. Then, we will summarize the results on the onset times of NPSs. Final, we will summarize the report findings on the association between NPSs and the cognitive impairment.

10We summarized the scales for measuring neuropsychiatric and behavioural symptoms, listed the measured symptoms, applicable population, and described each scale in Table 1. Multiple instruments are available for assessing NPSs in AD, but there are several problems that need to attention when selecting a measurement scale. First, since NPSs overlap with dementia symptoms, attempts should be made to rule out the effects of cognitive impairment on the measures. For example, the Behavioral Pathology in Alzheimer’s Disease Rating scale (BEHAVE-AD) is commonly used to assess non-cognitive behavioural disorders in patients with AD. Secondly, some scales are only applicable to subjects with a certain level of cognition. For example, the Hamilton depression scale (HAMD) is only used to assess patients with mild dementia; while the Depressive Signs Scale (DSS) cannot assess depressive symptoms in patients with mild or moderate dementia. In addition, multiple NPSs tend to occur simultaneously (e.g. apathy and depression), and the functional relationships among these different NPSs are not clear. It is recommended to adopt a scale that can measure multiple NPSs simultaneously, and all of them should be independent measurements, such as Neuropsychiatric Inventory (NPI) scale. Finally, the patient and the caregiver may exaggerate or conceal the severity of the symptoms because of the pathological injury and the caregiver’s emotions, respectively, so the instrument should be graded based on information from as many sources as possible, such as the Dimensional Apathy Scale.

11Therefore, although many scales have been developed to measure neuropsychiatric and behavioural symptoms, scales that can accurately measure different NPSs in patients with AD are still inadequate or lacking. In practice, we should carefully select appropriate scales according to the population to be assessed and their needs.

12Table 2 summarizes the study findings that provide information on the onset time of NPSs. For example, one study suggested that the prevalence of delusion was significantly increased in mild AD compared to aMCI; and another study showed that the prevalence of aberrant motor behaviours, delusion, hallucinations and sleep disturbances were significantly higher in moderate AD than in mild AD. For the purpose of this study, the AD continuum was divided into four stages as aMCI (or preclinical AD), mild AD, moderate AD, and severe AD, and these findings are summarized in sTable 1 and Fig. 1. sTable 1 shows that several studies have found that the prevalence of NPSs are significantly higher at a certain stage than at its previous one. Each rise of the curve in Fig. 1 represents at least one study suggesting a significant increase in the prevalence of the NPSs compared to the previous stage.

13Most NPSs occur in the preclinical AD or aMCI phase, including apathy, depression, anxiety, irritability, agitation, sleep disturbances, and abnormal motor behaviour (Fig. 1, sTable 1). Delusions and eating disturbances occur in the mild AD phase. Finally, disinhibition, hallucinations, and euphoria occur in the moderate AD phase. In addition to disinhibition and appetite changes, the onset of the other NPSs is progressive, meaning the prevalence of these symptoms continues increasing as the disease progresses.

14By collecting and sorting out the literature findings on the association between NPSs and cognitive decline, we found that NPSs were closely related to global cognitive impairment and activities of daily living decline. In general, different NPSs in patients with AD were related to specific cognitive impairment (Table 3, sTable 2). Mental symptoms and agitation seem to be associated with more cognitive domains and more rapid cognitive decline, all accompanied by impaired language and memory function. In addition, delusions are associated with decreased executive function, reasoning ability, and conceptualization; hallucinations are associated with decreased visuospatial function; while agitation is associated with decreased executive function, visuospatial function, and conceptualization. Apathy is closely related to executive function and comportment (which stands for Social Behavior). Depression are accompanied by a decline in executive and memory function. Abnormal motor behaviour is associated with executive and language impairment. Disinhibition and sleep disturbances are related only to executive and memory functions, respectively. However, we did not find that euphoria, irritability, or eating disturbances were associated with any specific cognitive domains. Hence, executive function is the most closely related to NPSs among all cognitive domains, implying the executive function deficits and some NPSs may stem from common neurobiological mechanisms.

15We summarized the neuroimaging findings of NPSs in AD (Table 4), of which approximately two-thirds used the NPI scale to evaluate NPSs and three-quarters used the NICDS-ADRDA criteria for the diagnosis of AD. Based on the reports we identified for this review, we defined the frequency of the lesion regions in the NPS-specific brain lesion pattern, and the high frequency represented that the region was most affected by the symptom (Figs. 2, 3, 4 and 5, sFigure 2–5). “Lesion” was defined as a pathological lesion associated with NPSs, including gray matter volume atrophy, cortical thinning, decreased white matter integrity, decreased metabolism, and increased Aβ deposition. In addition, brain circuits for apathy, depression, and anxiety in AD patients were also reviewed in this section.

16White matter studies on apathy consistently show that patients with low fractional anisotropy (FA)—a measure representing white matter integrity and information transfer speed—of the anterior cingulate cortex (ACC) are more likely to present with apathy symptoms. In addition, FA in the right thalamus and bilateral parietal lobes and white matter hyperintensities in the frontal lobe were correlated with apathy. Gray matter studies on apathy showed that gray matter atrophy in the bilateral ACC and left medial frontal cortex. Moreover, decreased gray matter density in the bilateral ACC, frontal cortex, head of the left caudate nucleus and bilateral putamen, and decreased cortical thickness in the left caudal ACC, left orbitofrontal cortex (OFC), left superior, and ventrolateral frontal region and inferior temporal region were all correlated with the severity of apathy.

17Positron emission tomography (PET) studies have demonstrated that the AD patients with apathy had glucose hypometabolism in the ACC, OFC, ventral striatum, and medial thalamus, higher neurofibrillary tangles burden in the ACC, and higher amyloid-β (Aβ) deposition in the bilateral frontal lobe and right ACC.

18Apathy has been conceptualized as a motivational barrier or defect in goal-directed behaviour. As reported, the normal motivational behaviour is related to the anterior cingulate-subcortical circuit. The anterior cingulate circuit, linking the ventral striatum to the thalamus via the rostromedial ventrolateral globus pallidus interna and ventral pallidum, originates in the ACC and medial OFC. The disruption of this circuit may be crucially involved in effort-based decision making and executive functions. In particular, lesions to the medial OFC and ventral striatum can lead to the inability to connect emotions with ongoing or upcoming behaviour.

19Apathy is the most common NPS in AD and has been the focus of past research on NPSs. Although the regions of apathy lesions are not the same in different studies, it is consistently shown that apathy is closely related to changes in the structure and function of the medial frontal cortex and the ACC in AD. Meanwhile, subcortical alterations in the ventral striatum, medial thalamus, and ventral pallidum are also related to apathy. The imaging findings in the regions of apathy lesion supports the association of apathy with anterior cingulate circuit lesions in AD (Fig. 2, sFigure 2).

20Depression associated gray matter volume atrophy and cortical thinning mainly occur in the frontal and temporal lobes, especially in the left dorsolateral prefrontal, right medial prefrontal, OFC, ACC, and inferior temporal gyrus. The severity of depression was also associated with gray matter changes in the right hippocampal, entorhinal, left parietal, and striatal regions. Similarly, depression causes white matter lesions in the frontal, parietal, and temporal lobes. Hypometabolism in the bilateral superior frontal, left anterior cingulate, and dorsolateral prefrontal regions have been noted in patients with depression. The presence of depression was also associated with the accumulation of Aβ in the frontal lobe in aMCI.

21Most research shows that depression is associated with frontal-striatal and subcortical limbic circuits in AD. Mayberg’s frontal-limbic model of depression involves the dorsal, ventral, and rostral compartments. The disturbances in the dorsal compartment, which includes the dorsolateral prefrontal, dorsal ACC, and posterior cingulate cortex, cause attentional and cognitive disturbances. The ventral compartment, which consists of the paralimbic cortical, subcortical, and brainstem regions, is associated with the vegetative and somatic symptoms of depression, such as insomnia and loss of appetite. The rostral ACC connects the dorsal and ventral compartments and plays an important regulatory role in the whole network.

22Other researchers believe that the hippocampus is the most common area of structural brain changes in depression, and is associated with prefrontal cortex damage. A hippocampal–prefrontal cortex model was proposed, in which the hippocampus—a central part of memory function—regulates mood disorders and cognitive dysfunction in depressed patients. The model also emphasizes the role of the limbic system, such as the cingulate gyrus and amygdala.

23Depression may precede a cognitive decline in AD and accelerate the rate of cognitive decline. Both depression and apathy were associated with structural brain changes in the frontal, temporal, and occipital lobes, but apathy was more associated with the anterior cingulate-subcortical circuit, and depression was more associated with neuropathology in the frontal-subcortical limbic circuits in AD (Fig. 3, sFigure 3). The subcortical limbic system of depression mainly includes the hippocampus, amygdala, locus ceruleus, substantia nigra, and hypothalamus.

24An anxiety state predicts a decreased entorhinal cortical volume and may be associated with amygdala atrophy. The severity of anxiety was also associated with hyperperfusion of the bilateral ACC, decreased gray matter volume in the right precuneus, inferior parietal, left parahippocampal, posterior cingulate gyrus, left insula, and bilateral putamen lobes, and hypometabolism in the bilateral entorhinal, anterior hippocampal, left superior temporal and insula regions. 18F-Florbetapir-PET studies show the patients with anxiety had higher Aβ deposition in the precuneus—posterior cingulate, frontal, parietal, anterior cingulate cortex and global cerebral. The locus coeruleus in the hypothalamus is also thought to be the centre of the anxiety-related network, and anxiety cells are enriched in the CA1 in the ventral hippocampus.

25Anxiety can be thought of as a set of expected emotional, cognitive, and behavioural changes to the uncertainty of potential future threats, accompanied by fear. The amygdala plays a pivotal role in the transmission and interpretation of fear and anxiety because it receives extensive afferents from the thalamus and extracortical sensory systems and as a subcortical visceral afferent pathway (Fig. 4). The neuronal interactions between the amygdala and cortical regions, such as the OFC, provide a framework for the initiation of coping behaviors based upon the nature of the threat and prior experiences. Grupe DW and Nitschke JB developed the ‘Uncertainty and Anticipation Model of Anxiety’, which emphasizes that activity in the dorsomedial prefrontal regions and OFC reflects probabilistic estimates of future events and expected costs, respectively, and mainly include the amygdala, bed nucleus of the stria terminalis (BNST), ventromedial prefrontal cortex, OFC, anterior mid-cingulate cortex and anterior insula.

26An alternative network is also proposed. Under this network, the hippocampus receives convergent, integrated inputs from all sensory systems through the projections of the entorhinal cortex, and it works with the entorhinal cortex on situational fear conditioning. Projections from the hippocampus to the BNST and projections from the BNST to hypothalamic and brainstem sites may be involved in the expression of contextual fear conditioning. Theta oscillations within the hippocampus-amygdala-medial prefrontal cortex circuit are associated with anxious behavior. Both this circuit and the ‘Uncertainty and Anticipation Model of Anxiety’ suggest that the amygdala plays a pivotal role in the assessment of, and response to, danger.

27Anxiety is more common in individuals with dementia than in those without dementia, and it has been described as a risk factor for AD. Anxiety is primarily associated with damage to the subcortical regions in AD: the amygdala plays an important role in risk assessment and response, the locus coeruleus plays an important role in the efferent response system, and the hypothalamus plays an important role in the integration of autonomic and neuroendocrine responses to threats. The anterior mid-cingulate cortex is closely linked to these brain regions and plays a central role in a series of maladaptive responses to uncertainty (Fig. 4, sFigure 4).

28Delusions are characterized by asymmetrical brain structure change in the frontal and temporal regions as well as mainly atrophy in the right temporal lobe and left frontal lobe. In addition, delusions are associated with gray matter change in the right hippocampus, left frontal lobe, right frontoparietal cortex, and left claustrum, and white matter changes in the bilateral frontal, parieto-occipital region, left basal ganglia, the body of the corpus callosum and the superior temporal gyrus. The severity of delusions is associated with hypometabolism in the frontal lobe, especially in the right lateral frontal cortex, ACC and OFC, but the association with metabolism in the temporal lobe and occipital lobe is inconsistent. Some studies showed delusions had hypometabolism in the bilateral temporal cortex and the left medial occipital region, while other studies showed delusions had higher metabolism in the superior temporal, left inferior temporal gyrus and inferior parietal lobe or no connection. The discrepancies among previous studies are likely due to sex differences. One study showed that women with delusions had frontotemporal atrophy in AD, but men with delusions did not have brain atrophy compared to men without delusions.

29Hallucinations are associated with atrophy of the gray matter in the anterior right insula, left superior frontal gyrus, lingual gyrus and lateral occipital lobes in AD, as well as hypometabolism in the right ventral and dorsolateral prefrontal areas. Patients with hallucinations also had hypoperfusion in the parietal lobe. The damaged brain areas associated with hallucinations mainly include the anterior (e.g., dorsolateral prefrontal area) -posterior (e.g., occipital lobes) neural network and the anterior insula. It is worth noting that these studies do not distinguish between the types of hallucinations. The most common form of hallucinations is visual in AD. Visual hallucinations are mainly caused by atrophy and white matter lesions in the occipital lobe. These lesions are related to the disturbance in the lateral frontal cortex, namely, the ventral visual stream system.

30Both delusions and hallucinations occur in the middle or late AD stage, and hallucinations may be more common in severe dementia. Compared to delusions, only a limited number of studies have looked specifically at hallucinations in AD, so researchers seem to focus more on delusions (despite conflicting evidence and patients clinging to false beliefs). The brain lesions of delusions mainly occur in the frontotemporal lobe, accompanied by lateralization and sex differences, while brain lesions of hallucinations mainly occur in the anterior-posterior neural network and anterior insula region (Fig. 5, sFigure 5).

31Hyperactivity syndrome includes agitation, disinhibition, irritability, euphoria, and aberrant motor behavior, which is related to increased functional connectivity in the anterior cingulate cortex and right insula areas of the salience network. Other neuroimaging findings support this view, especially for the agitation. Diffusion tensor imaging studies showed that irritability and agitation are related to the decreased white matter integrity in the ACC, which is a core component of the salience network. Magnetic resonance imaging studies showed that agitation is related to greater atrophy in the frontal, cingulate, insular, amygdala, and hippocampal regions while aberrant motor behaviour is related to greater atrophy in the amygdala. These are predominantly frontolimbic regions and compose many components of the significance network. PET studies showed that aberrant motor behaviour is associated with hypometabolism of the striatum and frontotemporal lobes and hypermetabolism of the OFC. In addition, a study found that the severity of the agitation is correlated with the atrophy score of the posterior temporal lobe.

32AD patients sometimes suffer from eating disturbances and weight loss, and nearly half of patients with AD experience appetite changes in the mild stage. A longitudinal study found that patients had accelerated weight loss as many as 6 years before the diagnosis of AD. A functional neuroimaging study found hypoperfusion of the ACC, OFC, and left middle mesial temporal cortices can predict appetite disturbances. Other neuroimaging studies found weight loss is associated with atrophy of the mesial temporal cortex and hypometabolism of the ACC. In addition, the amygdala and OFC affect the internal balance between hunger and satiety and external motivational control of appetite. Therefore, eating disturbances may be related to the network of the ventral (orbitobasal) frontal cortex, medial temporal cortex, and amygdala in AD.

33Common sleep disturbances in AD include fragmentation of sleep at night, decreased duration of sleep at night, daytime sleepiness, and inversion of the sleep-wake cycle. The relationship between sleep and AD is complex and bidirectional, and the underlying mechanism is the interaction between sleep and Aβ—sleep disturbances increase the generation of Aβ and decrease the elimination of Aβ; and once Aβ accumulates, there is increased sleep disturbance. Amyloid deposition appears to be associated with decreased sleep quality, but not with changes in sleep quantity in the preclinical stage of AD. Worse sleep quality increases the Aβ burden in the precuneus, and a shorter sleep quantity at night increases the Aβ burden in the right hippocampus and thalamus in healthy older peoples. In addition, tau pathology as the second hallmark of AD can also cause sleep disturbances. Sleep regulating areas mainly include the brain stem, thalamus, hypothalamus, midbrain and basal forebrain. Many of these areas show tau pathology at pretangle stages or stages by Braak staging, before any cortical tau or amyloid pathology development. Orexin, as an important sleep-wake regulatory marker, increases in the cerebrospinal fluid in patients with moderate to severe AD and is positively correlated with tau protein levels. Hence, tau pathology may also play an important role in sleep disturbances in AD.

34Dysfunction of the orbitofrontal–subcortical circuit is characterized by personality changes including disinhibition, agitation, and irritability; this circuit connects the frontal monitoring systems to the limbic system. Few studies on the relationships between other NPSs and neuroimaging have been conducted in AD, but they all are associated with a lesion in the ACC (Fig. 5, sFigure 5).

35Behavioral and neuropsychiatric symptoms are associated with abnormalities in specific brain regions, such as the prefrontal and subcortical limbic regions, which disrupt the normal balance of neurotransmission. According to neuroimmunoregulation theory, this, in turn, is associated with inflammatory pathways that lead to microglial activation and aggregation and the formation of neurofibrillary tangles, ultimately triggering neuronal loss. In addition, NPSs are related to the dysfunction of various neurotransmitter pathways related to AD, including the dopamine system, the serotonin system, and the cholinergic system. In the current section, we will further discuss the molecular and cellular changes associated with stages of AD progression and their relationship to NPSs.

36NPSs are variable and sporadic throughout the course of the disease, but an important group appears early (Fig. 1), especially emotional symptoms (e.g., depression, anxiety, and apathy), before the clinical diagnosis of cognitive impairment.

37The presence of microglial activation and inflammatory signals in patients with AD prior to “clinical diagnosis” may explain the occurrence of NPSs in the early stages of the disease. Activation of microglia has been shown to be associated with deficits in social interaction. Meanwhile, apathy, anxiety, depression, and agitation were associated with increased pro-inflammatory cytokines (systemic tumor necrosis factor α) detected in the serum of AD patients. Similarly, another study found an association between the levels of diverse cytokines present in CSF of patients with dementia, discovering that anti-inflammatory interleukin-6 (IL-6) cytokine levels were inversely proportional to anxiety scores in AD patients. Importantly, Ledo et al. found that depressive-like behavior induced by Alzheimer’s Aβ oligomers in mice is mediated by inflammation through microglial cell activation in the hippocampus, decreasing 5-HT levels in the hippocampus and prefrontal cortex.

38Depression is also influenced by the reduction of dopamine and serotonin in the brain, while AD has been associated with loss of serotonergic neurons and a decrease in 5-hydrotryptamine (5-HT) levels in the postmortem brains with this disease. In a healthy brain, dopamine is constantly released into the hippocampus, which links emotional feelings with cognitive processes. In AD, a decrease in dopamine levels coupled with a decrease in serotonin triggers depression, which is regarded as a prodromal symptom of AD. In addition, late-life depression and AD share common genetic factors, including brain-derived neurotrophic factor, apolipoprotein E, interleukin-1, and methylenetetrahydrofolate reductase, while inflammatory pathways are activated in both disorders. In this context, the changes produced by late-life depression seem to have an impact on the hippocampus, inducing inflammatory events that activate microglia, which trigger the overproduction of pro-inflammatory cytokines, as described in earlier time about the conceptual scheme of the neuroimmunomodulation theory.

39As AD progresses, most NPSs present in the early stages of AD become more severe and common, and some psychiatric and behavioral symptoms begin to appear. One hypothesis that has been suggested is that AD progressive cholinergic loss (resulting in a loss of inhibition of the dopamine system), in the context of a relatively spared dopaminergic system, may increase the tendency of AD patients to develop psychosis because of a relative striatal hyperdopaminergia. Available evidence suggested that striatal dopamine (D2/D3) receptors are increased in AD patients with delusional compared with AD patients without delusions, and that higher striatal D2 receptors are associated with wandering behavior.

40In addition, several studies have shown a correlation between serotonin deficiency and NPSs. In patients with AD, lower levels of serotonin1A receptors were associated with more severe depressive symptoms, and lower concentrations of serotonin in the temporal cortex were associated with hyperactivity and psychosis. The depressed AD patients showed larger and more extensive reductions in serotonin transporters including the midbrain, nucleus accumbens, and thalamus. Further, the study showed glucose metabolism in the right dorsolateral prefrontal cortex was positively correlated with 5-HT transporter ([11C]-DASB) levels in the striatum in AD patients, suggesting that subcortical serotonergic dysfunction may affect cortical function in regions involved in affective processing such as dorsolateral prefrontal cortex. For example, prefrontal cortex interactions with the hypothalamus mediate reward aspects of eating such as food cravings.

41In the final stage of AD, the pathology of all NPSs becomes complicated and difficult to treat. Worsening mental symptoms (delusions and hallucinations) cause confusion between reality and morbid fantasies, and patients exhibit severe abnormal motor behaviour, often characterized by scratching, which can lead to recurrent hyperfascial skin infections. These destructive NPSs accelerate the death of AD patients.

42We believe that there may be two connective mechanisms between NPSs and AD: (A) NPSs arise as a consequence of AD pathology. AD affects key brain regions of underlying behavior, emotion, or mental, so NPSs may be a direct non-cognitive manifestation of AD neurodegenerative disease. AD-related cognitive decline may also develop into depression, anxiety, or similar NPSs as a psychological response. Other NPSs in the AD stage are caused by AD through reverse causality or psychological responses, and the onset of NPSs will aggravate the pathology of AD. (B) NPSs and AD pathology arise as a consequence of some shared pathologic process. In this case, there is no causal relationship between NPSs and AD pathology, but a third factor, such as brain vascular disease or white matter change, leads to the occurrence of AD and NPSs.

43NPSs almost universal existence in the AD, combined with their disabling effects on patients and caregivers, is contrasted by the fact that few effective and safe treatments exist, which is mainly attributed to the following three reasons: (1) Lack of reliable and effective measurement of NPSs in AD; (2) Biomarkers associated with symptom-specific in patients with AD have not yet been developed; (3) The relationship between NPS and the pathological mechanism of AD remains unclear.

44The current review provides a good complement to these treatment issues. Firstly, we summarized the detailed scale information, as well as some possible problems in the NPSs measurement process, which may be helpful for accurate assessment of NPSs. Next, we described symptom-general and -specific patterns of brain lesions. The anterior cingulate cortex is a commonly damaged region across all symptoms, and the prefrontal cortex, especially the orbitofrontal cortex, is also a critical region associated with most NPSs. This conclusion was supported by an intervention study, which found that greater reduction in orbitofrontal blood flow has been associated with a greater behavioural response to treatment with donepezil.

45In contrast, the anterior cingulate-subcortical circuit is specifically related to apathy in AD, the frontal-limbic circuit to depression, and the amygdala circuit to anxiety. Understanding symptom-specific brain lesion networks may help track treatment response for targeted drug therapy. For example, it is important to understand whether observed network changes are the result of functional remodeling of defective networks or reflect the plasticity of compensatory circuitry complement in treatment development. Finally, we elucidated the two possible connective mechanisms between NPSs and AD: etiologic pathways and interactions, and summarized the onset time of NPSs. Different NPSs occur in different disease stages of AD, but most symptoms appear in the preclinical AD or mild cognitive impairment stage and develop progressively, which suggested that the critical treatment window for NPSs should be advanced to the early stage of AD.

46There are still some limitations in the study of the pathological mechanism of NPSs in AD patients, and more studies are needed to solve them in the future. Firstly, we found the differences between the subtypes of each symptom in exploring the NPS-specific pathologic mechanisms. For example, in addition to the weight loss caused by the loss of appetite mentioned above, AD patients may also experience increased appetite, difficulty swallowing, and other symptoms of eating disturbances. The relationship between dementia stages and eating disorders may depend on the type of eating disorder. For example, people with mild AD are more likely to experience anorexia, while people with moderate AD have an increased appetite and changes in food preferences and eating habits, and people with severe AD have difficulty swallowing. We suspect that in AD, the relationship between the dementia stage and other NPSs may also differ depending on the subtype of symptoms. Therefore, future studies should further explore the relationship between various symptom subtypes and the severity of dementia in order to better understand the pathological association.

47In addition, we should pay attention to the pathological superposition of multiple NPSs. One type of NPSs is unlikely to appear alone and instead is most likely to occur with other types of symptoms in AD. Among patients with dementia, 55% report two or more symptoms, and 44% report three or more symptoms. However, most studies, including some included in the current review, did not adjust the presence of other NPSs when exploring the mechanism of a particular NPS. This is a major limitation of the current review.

48Some longitudinal studies showed that individuals with two NPSs had an additional 1.9-fold elevated risk of developing dementia compared with those with zero or one NPS, while those with three or more symptoms had an additional risk of 3 and significantly higher odds of having functional limitations. Another study also showed the number of comorbid NPSs, but not symptom clusters, are associated with an increased risk of dementia. These findings suggest that understanding the comorbid pattern of NPSs will help us to further clarify the pathogenesis of NPSs in AD and contribute to clinical evaluation. However, there are few neuroimaging studies on comorbid NPSs and future studies should focus on this issue.